Pharmacological advances in the treatment of invasive candidiasis

References

• Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infections due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the Scope Program. Diagn Microbiol Infect Dis. 30, 121–129 (1998).
   PubMed Web of Science ®Google Scholar
• Kao AS, Brandt ME, Pruitt WR et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29, 1164–1170 (1999).
   PubMed Web of Science ®Google Scholar
• Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148, 2642–2645 (1988).
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin. Infect. Dis. 33, 177–186 (2001).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new ‘gold standard’. Clin. Infect. Dis. 37, 415–425 (2003).
   PubMed Web of Science ®Google Scholar
• Amphocin (amphotericin B) package insert. Pharmacia, MI, USA (2001).
   Google Scholar
• Graybill JR, Craven PC. Antifungal agents used in systemic mycoses. Drugs 25, 41–62 (1983).
   PubMed Web of Science ®Google Scholar
• Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8, 17–41 (1983).
   PubMed Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12, 308–329 (1990).
   PubMedGoogle Scholar
• Patterson RM, Ackerman GL. Renal tubular acidosis due to amphotericin B nephrotoxicity. Arch. Intern. Med. 127, 241–244 (1971).
   PubMedGoogle Scholar
• Douglas JB, Healy JK. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am. J. Med. 53, 77–84 (1972).
   Google Scholar
• Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331, 1325–1330 (1994).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin with amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29, 1402–1407 (1999).
   PubMed Web of Science ®Google Scholar
• Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am. J. Med. Sci. 298, 299–304 (1989).
   PubMed Web of Science ®Google Scholar
• Llanos A, Cieza J, Bernardo J et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. 40, 302–308 (1991).
   PubMed Web of Science ®Google Scholar
• Branch RA. Prevention of amphotericin B-induced renal impairment. Arch. Intern. Med. 148, 2389–2394 (1988).
   PubMed Web of Science ®Google Scholar
• Tynes BS, Utz JP, Bennett JE, Alling DW. Reducing amphotericin B reactions. Am. Rev. Respir. Dis. 87, 264–268 (1963).
   PubMed Web of Science ®Google Scholar
• Burks LC, Aisner J, Fortner CL, Wiernik PH. Meperidine for the treatment of shaking chills and fever. Arch. Intern. Med. 140, 483–484 (1980).
   PubMedGoogle Scholar
• Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 340, 764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin. Infect. Dis. 41, 301–307 (2005).
   PubMed Web of Science ®Google Scholar
• Abelcet® (amphotericin B lipid complex) package insert. Enzon, NJ, USA (2002).
   Google Scholar
• AmBisome® (amphotericin B liposome) package insert. Fujisawa, IL, USA (2002).
   Google Scholar
• Noskin GA, Piettrelli L, Coffey G et al. Amphotericin B colloidal dispersion for the treatment of candidemia in immunocompromised patients. Clin. Infect. Dis. 26, 461–467 (1998).
   PubMed Web of Science ®Google Scholar
• Diflucan® (fluconazole) package insert. Pfizer Inc, NY, USA (2004).
   Google Scholar
• Sporanox® (itraconazole) package insert. Janssen Pharmaceutica Products, NJ, USA (2004).
   Google Scholar
• Vfend® (voriconazole) package insert. Pfizer Inc., NY, USA (2005).
   Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Mohr JF, Finkel KW, Rex JH et al. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob. Agents Chemother. 48, 3151–3153 (2004).
   PubMedGoogle Scholar
• Cancidas® (caspofungin) package insert Merck & Co Inc., NJ, USA (2005).
   Google Scholar
• Mycamine® (micafungin) package insert. Astellas Inc., IL, USA (2005).
   Google Scholar
• Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A. Transpl. Infect. Dis. 6, 110–116 (2004).
   PubMedGoogle Scholar
• Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infection. Clin. Microbiol. Rev. 9, 499–511 (1996).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin. Infect. Dis. 33, 1959–1967 (2001).
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3, 685–702 (2003).
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trends of the hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin. Infect. Dis. 35, 627–630 (2002).
   PubMed Web of Science ®Google Scholar
• Rangel-Frausto MS, Wiblin T, Blumberg HM et al. National epidemiology of mycoses survey (NEMIS): variation in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin. Infect. Dis. 29, 253–258 (1999).
   PubMed Web of Science ®Google Scholar
• Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24, 1122–1128 (1997).
   PubMed Web of Science ®Google Scholar
• Colombo AL, Perfect J, DiNubile M. Global distribution and outcomes for Candida species causing invasive candidiasis. Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22, 470–474 (2003).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and epidemiology of Iowa organisms study. J. Clin. Microbiol. 40, 1298–1302 (2002).
   PubMed Web of Science ®Google Scholar
• Safran DB, Dawson E. The effect of empiric and prophylactic fluconazole on yeast isolates in a surgical trauma intensive care unit. Arch. Surg. 132, 1184–1189 (1997).
   PubMedGoogle Scholar
• Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin. Infect. Dis. 35, 1073–1080 (2002).
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24, 235–247 (1997).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J. Clin. Microbiol. 40, 852–856 (2002).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole, and voriconazole of isolates collected 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39, 33254–33259 (2001).
   Google Scholar
• Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistance isolates. Antimicrob. Agents Chemother. 47, 1068–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Hazen KC, Baron EJ, Colombo AL et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J. Clin. Microbiol. 41, 5623–5632 (2003).
   PubMedGoogle Scholar
• Duswald KH, Penk A, Pittrow L. High-dose therapy with fluconazole greater than or equal to 800 mg per day. Mycoses 40, 267–277 (1997).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al. Activities of voriconazole, posaconazole, and fluconazole against 3,932 Candida species and 237 Cryptococcus neoformans: report from ARTEMIS global antifungal surveillance program, 2001–2002. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA (2003).
   Google Scholar
• Pappas PG, Rex JH, Sobel JD et al. Guidelines for the treatment of candidiasis. Clin. Infect. Dis. 38, 161–189 (2004).
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 366, 1435–1442 (2005).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH. Voriconazole for salvage treatment of candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22, 651–655 (2003).
   PubMed Web of Science ®Google Scholar
• Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocomprimised patients. Clin. Infect. Dis. 33, 1447–1454 (2001).
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36, 1221–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Chertow GM et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32, 686–693 (2001).
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39, 743–746 (2004).
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49, 3640–3645 (2005).
   PubMed Web of Science ®Google Scholar
• Reboli A, Rotstein C, Pappas P et al. Anidulafungin vs fluconazole for treatment of candidemia and candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. (Abstract M-718) (2005).
   Google Scholar